Mokari Atabak sold $3.2M of CORT

Mokari Atabak (Chief Financial Officer) sold 40,000 shares of CORCEPT THERAPEUTICS INC (CORT) at an average of $81.15 ($80.02–$82.45, $3.25M total) across 4 trades on 2026-06-15 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Mokari Atabak
Published Jun 17, 2026, 8:30 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jun 17, 2026, 8:32 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CORT
Neutral
medium confidence
Mentioned
$CORT
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CORTNeutralLow
01

Why it matters

The disclosure provides a fresh, timestamped data point on insider activity (CFO selling ~$3.25M), but it does not include any new operational or financial guidance that would directly reset valuation expectations.

02

Market read

Useful for monitoring insider behavior and potential sentiment, but likely low incremental trading impact absent other catalysts.

03

What to watch

Traders may over-weight insider sales; without concurrent guidance, trial, or deal news, the signal is mostly sentiment/positioning rather than valuation.

Relevance 5/10Novelty 8/10Timing: Filed 2026-06-17; sale executed 2026-06-15

Background

The article is an SEC Form 4 insider transaction disclosure for Corcept Therapeutics, reporting an officer sale executed across multiple trades.

Company-level read

Ticker impact

$CORTNeutralMedium confidence
Context

Corcept Therapeutics CFO Mokari Atabak sold 40,000 shares in open-market transactions on 2026-06-15 for ~$3.25M under a 10b5-1 plan.

Expected impact

Likely limited immediate impact; any reaction should be small unless accompanied by other company-specific catalysts.

Evidence & confidence

The filing is primary-source and time-stamped, but it is an officer sale under a pre-arranged plan with no accompanying fundamental change disclosed in the text.

Market effects

No sector read-through; this is a single-company insider transaction with no new regulatory/clinical/product information.

None indicated.

None indicated.

Counterpoint

10b5-1 sales often reflect scheduled liquidity rather than bearish expectations; the sale may not change near-term fundamentals.

Key entities

  • Corcept Therapeutics Inc

    Subject of the Form 4 insider transaction; CFO Mokari Atabak sold shares on 2026-06-15.

  • Mokari Atabak

    Chief Financial Officer who executed the open-market sale under a pre-arranged Rule 10b5-1 plan.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CORTMedAI 8/10

Corcept reports 8-year response in vulvar cancer case study

Corcept Therapeutics (CORT) reported a case study in ESMO Rare Cancers showing an 8-year response to relacorilant plus nab-paclitaxel in a metastatic vulvar cancer patient. The company noted this is a single case and not representative of the broader population. Relacorilant is FDA-approved for platinum-resistant ovarian cancer but not vulvar cancer. Corcept is developing the drug for other cancer types.

$CORTMed

Corcept Therapeutics Inc (CORT) (Q3 2026) Earnings Call Highlights: Revenue Surges 64%

Corcept Therapeutics (CORT) reported Q3 2026 revenue of $91M, up 64% YoY, driven by Lifyorli's growth. Management expects Lifyorli to move earlier in treatment sequences and sees potential for $1B in revenue. The company reiterated its 2026 guidance of $1.1B-$1.2B, citing strong performance in endocrinology and oncology. CEO Belanoff discussed upcoming clinical trials and potential combinations for Lifyorli.

$CORTMedAI 8/10

Corcept Therapeutics Q3 Earnings Call Highlights

Corcept Therapeutics (CORT) reported positive results from its BELLA Phase 2 trial, with relacorilant showing median progression-free survival of 7.2 months and a 59% response rate. The FDA is set to decide on relacorilant's application for Cushing's syndrome by December 17. Corcept also outlined ongoing trials for relacorilant in various cancers and miricorilant in MASH, with results expected by 2027. The company plans to initiate a Phase 3 ALS study next year.